This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

An interesting secondary finding of the recently reported retrospective analysis by Sin and Man¹ was that higher doses of inhaled corticosteroids failed to reduce the frequency of emergency department (ED) visits compared with lower doses.¹ My colleagues and I recently performed a similar retrospective analysis stratified by type of inhaled corticosteroid to determine if the more potent agent fluticasone propionate (Flovent; GlaxoSmithKline, Research Triangle Park, NC) reduced ED visits compared with the less potent agents beclomethasone dipropionate (Beclovent; GlaxoSmithKline) and triamcinolone acetonide (Azmacort; Aventis Pharmaceuticals Inc, Bridgewater, NJ).

A total of 308 patients were identified as having been admitted to a city-county hospital with a primary diagnosis of asthma (International Classification of Diseases, Ninth Revision, Clinical Modification² codes 493.0, 493.1, and 493.9) between January 1, 1997, and November 1, 1999. Patients were stratified by discharge inhaler, and each patient was followed up for exactly 1 year after discharge. During . . . [Full Text of this Article]

RELATED ARTICLES

Potency of Inhaled Corticosteroid Fails to Predict Reduced Emergency Department Visits
Don D. Sin and S. F. Paul Man
Arch Intern Med. 2003;163(2):248-249.
EXTRACT | FULL TEXT  

Low-Dose Inhaled Corticosteroid Therapy and Risk of Emergency Department Visits for Asthma
Don D. Sin and S. F. Paul Man
Arch Intern Med. 2002;162(14):1591-1595.
ABSTRACT | FULL TEXT